Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of enecadin in acute ischemic stroke (TEST Phase IIa)
2005-003783-27Phase 2Terminated
- Sponsor
- PAION AG
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enecadin in ischemic stroke (4 arms), sponsored by PAION AG. Primary endpoint: Safety parameters. Started Sep 2005; status: terminated.
02
Drugs
enecadin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2005-003783-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003783-27.